Espero BioPharma Inc, a pharmaceutical company, has expanded its collaborative partnering effort for its tecarfarin, it was reported on Thursday.

The product is a Phase III-ready, vitamin K antagonist, taken once a day as an oral anticoagulant and is aimed at a metabolic pathway that is distinct from the one targeted by the most commonly prescribed anticoagulants. Leading doctors are of the opinion that Blood-thinning drugs may be effective in treating Corona Virus Disease 2019 (COVID-19) patients, raising hopes of a major breakthrough in the race to find a treatment for the deadly virus.

Quang Pham, chairman and chief executive of Espero BioPharma, said, 'The pathogenesis of hypercoagulability in COVID-19 is not completely understood. This current global pandemic and unmet needs in anticoagulation underscores the importance of tecarfarin as a potential new therapy for managing patients. We are accelerating our partnering efforts for tecarfarin to potentially bring this investigative therapy to patients more quickly.'